Please Wait
Applying Filters...
menu
    • menu
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-03

    Virtual Booth

    An Enquiry

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Ziftomenib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 317,847Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Kura Oncology Gets $30M Milestone Payment For Ziftomenib AML
    Kura Oncology Gets $30M Milestone Payment For Ziftomenib AML

    24 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/24/3172720/35186/en/Kura-Oncology-Receives-30-Million-Development-Milestone-Payment-in-Ziftomenib-AML-Program-with-Kyowa-Kirin.html

    GLOBENEWSWIRE
    24 Oct 2025
    Share Share
    Kura Oncology, Kyowa Kirin Initiate Trial For AML Patients
    Kura Oncology, Kyowa Kirin Initiate Trial For AML Patients

    01 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/01/3159367/35186/en/Kura-Oncology-and-Kyowa-Kirin-Launch-Clinical-Trial-Evaluating-Dual-Inhibition-of-NPM1-and-FLT3-Mutations-in-Patients-with-Newly-Diagnosed-Acute-Myeloid-Leukemia-AML.html

    GLOBENEWSWIRE
    01 Oct 2025
    Share Share
    Kura, Kyowa Kirin Dose First Patient in AML Ph 3 Trial
    Kura, Kyowa Kirin Dose First Patient in AML Ph 3 Trial

    29 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/29/3158094/35186/en/Kura-Oncology-and-Kyowa-Kirin-Announce-First-Patient-Dosed-in-Pivotal-Phase-3-KOMET-017-Trial-of-Ziftomenib-for-Frontline-Acute-Myeloid-Leukemia-AML.html

    GLOBENEWSWIRE
    29 Sep 2025
    Share Share
    Kura Oncology, Kyowa Kirin Publish Ziftomenib Data
    Kura Oncology, Kyowa Kirin Publish Ziftomenib Data

    25 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/25/3156758/35186/en/Kura-Oncology-and-Kyowa-Kirin-Announce-Publication-of-Pivotal-Ziftomenib-Data-in-Relapsed-Refractory-NPM1-Mutated-AML-in-the-Journal-of-Clinical-Oncology.html

    GLOBENEWSWIRE
    25 Sep 2025
    Share Share
    Kura Oncology and Kyowa Kirin Report Positive Data for Ziftomenib
    Kura Oncology and Kyowa Kirin Report Positive Data for Ziftomenib

    12 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/12/3098218/35186/en/Kura-Oncology-and-Kyowa-Kirin-Report-Positive-Updated-Combination-Data-for-Ziftomenib-in-Newly-Diagnosed-AML-at-2025-European-Hematology-Association-Congress.html

    GLOBENEWSWIRE
    12 Jun 2025
    Share Share
    Kura Oncology, Kyowa Kirin Report Positive Ziftomenib Data
    Kura Oncology, Kyowa Kirin Report Positive Ziftomenib Data

    02 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/02/3092389/35186/en/Kura-Oncology-and-Kyowa-Kirin-Report-Positive-Pivotal-Ziftomenib-Monotherapy-Data-at-2025-ASCO-Annual-Meeting.html

    GLOBENEWSWIRE
    02 Jun 2025
    Share Share